Technical analysis of Centessa Pharmaceuticals plc (CNTA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Price Performance
| 1 month | +0.00% |
| 3 months | +1.20% |
| Year-to-date | +61.94% |
| 1 year | +85.35% |
| 3 years | +524.04% |
| 5 years | +115.65% |
52-Week Range
| 52-week High | $40.56 |
| 52-week Low | $12.75 |
| Avg Volume (90d) | 2.4M |
Technical Indicators
| SMA 50 | $39.76 |
| SMA 200 | $29.63 |
| Beta | 1.26 |
| 30-day Volatility (annualised) | 3.5% |
| Price vs SMA 50 | +1.9% |
| Price vs SMA 200 | +36.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $24.90 | |
| 2025-11 | $29.03 | +16.6% |
| 2025-12 | $25.01 | -13.8% |
| 2026-01 | $24.57 | -1.8% |
| 2026-02 | $26.86 | +9.3% |
| 2026-03 | $39.72 | +47.9% |
| 2026-04 | $39.42 | -0.8% |
| 2026-05 | $39.76 | +0.9% |
| 2026-06 | $40.50 | +1.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $40.50 |
| Market Cap | $6.3B |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 12.76 |
| EV / EBITDA | -23.84 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 9.53 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.85 |